Cardioprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors Regardless of Type 2 Diabetes Mellitus: A Meta-analysis

Abstract

Around 63 million people present heart failure worldwide, 1,2 and this condition costs billion dollars to health care, 3 This syndrome is associated with high morbidity and mortality rates, since it has a poor prognosis due to the difficulty in recognizing high-risk and pre-clinical stage patients linked to the problem of an appropriate early treatment. 1,4,5 Despite many designed trials, no adequate pharmacological treatment was found for heart failure with preserved ejection fraction (EF>50%) [6][7][8] , which most likely represents 65% of heart failure in 2020. 1,6 Among the remarkable consequences of heart failure is the cardiorenal syndrome. 9 This link is attributed to renal hypoperfusion, which is caused by high venous pressure